The company said it is no longer pursuing prescriptions for digital therapeutics and is instead switching to over-the-counter sales. The decision comes as digital therapeutics companies have struggled to get insurers to cover software-based medical treatments.
In January Akili also laid off 48 workers, according to the outlet.
Alkili’s one FDA-approved product, EndeavorRx, is a video game designed to treat attention deficit hyperactivity disorder.
“We have seen the non-prescription model play out with EndeavorOTC, which we released in June as a treatment for adults with ADHD. In its first three months on the market, consumer demand, engagement and retention all surpassed our expectations,” Akili CEO and co-founder Eddie Martucci said. “We believe that our shift to a consumer-led model across our business will maximize our reach in the ADHD patient community and allow us to potentially expand into other large markets, without many of the high-cost centers of a prescription model.”
